Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült Államok2. fázis

Naxitamab Enabled Transplant-Free Study in High-Risk Neuroblastoma

A legfontosabb adatok

Ki végzi
Giselle Sholler
Hol
Hershey (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
101 fő, tervezett
Kezdés
2026. nov. 26.
Várható befejezés
2040. nov. 26.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Naxitamab and GM-CSF in combination with irinotecan and temozolomide
  • Dinutuximab. Immunotherapy
  • DFMO
A regiszteradat frissítve
2026. november 16.

Ki vehet részt

Életkor
1 év – 30 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 2 feltétel megnézéseKevesebb

Ki vehet részt

  • Age; Participants must be age ≤ 21 years at High-Risk NB diagnosis; Participants must be >12 months of age at enrollment. Diagnosis; Participants must have a pathologically confirmed diagnosis of neuroblastoma and classified as high risk by the criteria used by COG or SIOPEN at the time of diagnosis; Exception: patients who are initially diagnosed as non high-risk neuroblastoma, but later converted to high-risk neuroblastoma are also eligible; Prior Therapy; Participants must have completed standard induction therapy for initial diagnosis of high-risk neuroblastoma (5-7 cycles of induction chemotherapy with or without anti-GD2 antibody as per section 4.2, may include an additional cycle of therapy given prior to starting HRNB induction), and local control (surgery). Participants will enroll after completion of upfront induction therapy; Disease Response; Participants must have a disease response by revised 2017 International Neuroblastoma Response Criteria (INRC) at the end of standard 5-7 cycles of Induction of GEIR:; o Overall INRC Response ≥PR or; o Primary tumor ≥SD, AND soft tissue/metastatic bone ≥PR, AND bone marrow ≥MD*; Includes bone marrow response of minimal disease or complete response. Timing; Start of therapy to occur ≤ 45 days after completion of last induction cycle (from last day of cycle); Organ Function Requirements; Hematological: Hematological recovery as defined by ANC ≥750/μL (unsupported- >24 hrs off G-CSF and 7 days off pegylated filgrastim); Renal: Participants must have adequate renal function defined:; o For participants < 17 years old: estimated Glomerular Filtration rate (eGFR) as calculated from the Bedside Schwartz equation (in units of mL/min/1.73 m2) or via radioisotope GFR of ≥ 70 mL/min/1.73 m2. The Bedside Schwartz equation is: [(0.413) X (Height in cm)] / SCr; o For participants ≥17 years old: estimated Glomerular Filtration rate (eGFR) as calculated from the Cockcroft and Gault formula (in units of mL/min/1.73 m2) or via radioisotope GFR of ≥ 70 mL/min/1.73 m2. The Cockcroft and Gault formula is: [(140-age) x (Wt in kg) x (0.85 if female)] / (72 x SCr); Cardiac: Adequate cardiac function defined as:; Shortening fraction of ≥28%, or; Ejection fraction of ≥50%; Liver: Adequate liver function defined as:; Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age; ALT (SGPT) < 10 x upper limit of normal (ULN) for age; Post-pubertal study participants must be willing to use a highly effective contraceptive method (i.e., achieves a failure rate of <1% per year when used consistently and correctly) from the time of informed consent (and assent, as applicable) until 6 months after study treatment discontinuation. Participants who are lactating must agree to stop breast-feeding; Informed Consent: All participants and/or legal guardians must sign informed written consent. Assent, when appropriate, will be obtained according to institutional guidelines and applicable local regulations

Ki nem vehet részt

  • 1. Participants who are less than 1 year of age 2. Participants that had progressive disease (PD) at any time post cycle 4 during upfront induction therapy; Participants who required additional therapy after the end of standard Induction (5-7 cycles) to achieve adequate response; Investigational Drugs: Participants who are currently receiving another investigational drug are excluded from participation; Anti-cancer Agents: Participants who are currently receiving other anticancer agents are not eligible. Participants must have fully recovered from the hematological and bone marrow suppression effects of prior chemotherapy; Infection: Participants who have an uncontrolled infection are not eligible until the infection is judged to be well controlled in the opinion of the investigator; Participants who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study, or in whom compliance is likely to be suboptimal, should be excluded

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 1 és 30 év között vagy?

Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.

  • Penn State Milton S. Hershey Medical Center and Children's HospitalHershey, Egyesült ÁllamokContact: Penn State Clinical TrialsRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

A prospective, multicenter, clinical trial in participants with high-risk neuroblastoma that have completed induction therapy, evaluating the feasibility, efficacy, and toxicity of using anti-GD2 chemo-immunotherapy (naxitamab/irinotecan/temozolomide/GM-CSF) as consolidation followed by standard radiation, then standard anti-GD2 immunotherapy, and 2 years of DFMO maintenance.

A vizsgálat csoportja

  • Consolidation with anti-GD2 chemo-immunotherapy (naxitamab/irinotecan/temozolomide/GM-CSF)A vizsgált kezelés

    Consolidation Cycles 1-6: Naxitamab/Irinotecan/Temozolomide/GM-CSF + Radiation Immunotherapy Cycles 1-5: Dinutuximab + GM-CSF + Isotretinoin (or Dinutuximab-Beta) Immunotherapy Cycle 6: Isotretinoin alone DFMO Monotherapy: DFMO for 730 days (2 years)

    Kezelés: Naxitamab and GM-CSF in combination with irinotecan and temozolomide, Dinutuximab. Immunotherapy és DFMO

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Beat Childhood Cancer Research Consortium Phase II Trial of Transplant-Free Chemo-immunotherapy Consolidation Regimen With Naxitamab for High-Risk Neuroblastoma
Kérdések a feltételekről
Forrás: NCT07932808: ki vehet részt
A regiszteradat frissítve
2026. november 16.